Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 18/20 | 0.52 |
| ▸ | BMPR1A | P36894 | 7/20 | 0.51 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.46 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.46 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.46 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.46 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988761 | 0.87 | KDR (0.67) | KDRACVR1BMPR1ABMPR1BACVR2A | |
| SCHEMBL24409681 | 0.83 | ACVR1 (0.80) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL17442076 | 0.83 | ACVR1 (0.80) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL23988764 | 0.81 | ACVR1 (0.69) | KDRACVR1BMPR1ABMPR1BACVR2A | |
| SCHEMBL23988759 | 0.79 | ACVR1 (0.79) | KDRACVR1BMPR1ABMPR1BACVR2A | |
| SCHEMBL23988765 | 0.79 | KDR (0.68) | KDRACVR1BMPR1ABMPR1BACVRL1 | |
| SCHEMBL23988882 | 0.77 | ACVR1 (0.70) | KDRACVR1BMPR1ABMPR1BACVR2A | |
| SCHEMBL23988702 | 0.73 | KDR (0.59) | KDRACVR1BMPR1ABMPR1BACVRL1 | |
| SCHEMBL23988686 | 0.72 | KDR (0.58) | KDRACVR1BMPR1ABMPR1BACVR2A | |
| SCHEMBL7618559 | 0.72 | KDR (0.77) | KDRACVR1BMPR1ABMPR1BTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021222875-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |